XNAS · Healthcare · Biotechnology
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.21 | -0.20 | +4.76% | $0 | ✅ Beat | +0.70% | +17.48% | — |
| 2026-03-30 | Q4 2025 | -0.27 | -0.18 | +33.33% | $0 | ✅ Beat | -1.75% | +7.89% | +16.67% |
| 2025-10-30 |
| Q3 2025 |
| -0.32 |
| -0.24 |
| +25.00% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.38 | -0.34 | +10.53% | $0 | ✅ Beat | -16.85% | -12.19% | -30.11% |
| 2025-03-27 | Q4 2024 | -0.53 | -0.40 | +24.53% | $0 | ✅ Beat | +1.48% | +4.86% | +6.61% |
| 2024-10-31 | Q3 2024 | -0.50 | -0.60 | -20.00% | $0 | ❌ Miss | +3.25% | +6.32% | -7.69% |
| 2024-08-01 | Q2 2024 | -0.63 | -0.50 | +20.63% | $0 | ✅ Beat | +3.29% | -4.05% | -22.25% |
| 2024-03-28 | Q4 2023 | -0.44 | -0.47 | -6.82% | $28,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.